Work

Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

Year: 2015

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-015-2689-8

Authors: Sandra P. D’ Angelo, Michelle R. Mahoney, Brian A. Van Tine, Douglas R. Adkins, Maria T. Grosse Perdekamp, Mercedes M. Condy, Jason J. Luke, Eliza Woodward Hartley, Cristina R. Antonescu, William D. Tap, Gary K. Schwartz

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, Mayo Clinic, Washington University in St. Louis, Carle Foundation Hospital, University of Chicago, Columbia University Irving Medical Center

Language: English

Topic: Vascular Tumors and Angiosarcomas

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Memorial Sloan-Kettering Cancer Center, National Institutes of Health, National Cancer Institute

Awards: Alliance Statistics and Data Management Center, Washington University/ Siteman Cancer Center Lead Academic Site, G4185274752, Alliance for Clinical Trials in Oncology Operations Center

OpenAlex ID: W1964700247

FWCI: 2.6

Cites: 34

Cited by: 30

Related to: 10